APOB and lung cancer: Results:APOB inhibition decreased the lung cancer risk in ever-smokers via ApoB (odds ratio [OR] 0.81, 95% confidence interval [CI] 0.70–0.92, p = 0.010), LDL (OR 0.82, 95% CI 0.71–0.96, p = 0.040), and TG (OR 0.63, 95% CI 0.46–0.83, p = 0.015) reduction by 1 standard deviation (SD), decreased small-cell lung cancer (SCLC) risk via LDL reduction by 1 SD (OR 0.71, 95% CI 0.56–0.90, p = 0.016), and decreased the plasma ceramide level and increased the neutral ceramidase level.